Gemcitabine Combined With Mistletoe in Treating Patients With Advanced Solid Tumors
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, use different ways to stop tumor cells from dividing so they stop growing or die. Mistletoe may slow the growth of tumor cells and may be an effective treatment for solid tumors.
PURPOSE: Phase I trial to study the effectiveness of combining gemcitabine with mistletoe in treating patients who have advanced solid tumors.
| Condition | Intervention | Phase |
|---|---|---|
|
Breast Cancer Colorectal Cancer Lung Cancer Pancreatic Cancer |
Dietary Supplement: mistletoe extract Drug: gemcitabine hydrochloride |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Phase I Study Of The Effect Of Mistletoe Extract, A Complementary Medicine Botanical, On Pharmacokinetics, Pharmacodynamics And Safety Of Gemcitabine In Patients With Advanced Solid Tumors |
| Estimated Enrollment: | 51 |
| Study Start Date: | July 2002 |
OBJECTIVES:
- Determine the maximum tolerated dose of gemcitabine and mistletoe in patients with advanced solid tumors.
- Determine the toxic effects of this regimen in these patients.
- Determine the pharmacokinetic effects of gemcitabine with and without mistletoe in these patients.
- Determine tumor response in patients treated with this regimen.
- Determine the time to neutrophil count recovery in patients treated with this regimen.
OUTLINE: This is an open-label, dose-escalation study.
Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and mistletoe subcutaneously daily starting on day 8 of course 1. Treatment repeats every 21 days for at least 3 courses in the absence of disease progression or unacceptable toxicity.
Patients receive escalating doses of gemcitabine and mistletoe in 2 stages.
- Stage I: Cohorts of 3-6 patients receive escalating doses of mistletoe in combination with a constant dose of gemcitabine until the maximum tolerated dose (MTD) of mistletoe is determined.
- Stage II: Cohorts of 3-6 patients receive escalating doses of gemcitabine in combination with the MTD of mistletoe as determined in stage I until the MTD of gemcitabine is determined.
In both stages, the MTD is defined as the dose preceding that at which 2 patients experience dose-limiting toxicity.
PROJECTED ACCRUAL: A total of 45-51 patients will be accrued for this study.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Histologically confirmed metastatic, recurrent, or unresectable locally advanced solid tumor, including one of the following:
- Breast or colorectal cancer that has failed first-line chemotherapy
- Non-small cell lung cancer
- Pancreatic Cancer
- No CNS metastases
Hormone receptor status:
- Not specified
PATIENT CHARACTERISTICS:
Age
- 18 and over
Sex
- Male or female
Menopausal status
- Not specified
Performance status
- ECOG 0-1
Life expectancy
- Not specified
Hematopoietic
- Absolute neutrophil count at least 1,500/mm^3
- Platelet count at least 100,000/mm^3
Hepatic
- Bilirubin no greater than 2.0 mg/dL
- No clinically significant hepatic dysfunction
Renal
- Creatinine no greater than 2.5 mg/dL
- No clinically significant renal dysfunction
Other
- Not pregnant or nursing
- Negative pregnancy test
- HIV negative
- No clinically significant unrelated illness (e.g., serious infection or organ dysfunction) that would preclude study tolerance
PRIOR CONCURRENT THERAPY:
Biologic therapy
- No prior mistletoe
Chemotherapy
- See Disease Characteristics
- No prior gemcitabine
- More than 30 days since prior chemotherapy and recovered
Endocrine therapy
- More than 30 days since prior glucocorticosteroid therapy
Radiotherapy
- Recovered from prior radiotherapy
Surgery
- Recovered from prior surgery
Other
- At least 30 days since prior investigational agents
- No other concurrent investigational agents
Contacts and Locations| United States, Maryland | |
| Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office | |
| Bethesda, Maryland, United States, 20892 | |
| Principal Investigator: | Patrick J. Mansky, MD | National Center for Complementary and Alternative Medicine (NCCAM) |
More Information
Additional Information:
Publications:
| ClinicalTrials.gov Identifier: | NCT00049608 History of Changes |
| Obsolete Identifiers: | NCT00044161 |
| Other Study ID Numbers: | CDR0000258130, NCCAM-02-AT-260, NCI-02-AT-0260 |
| Study First Received: | November 12, 2002 |
| Last Updated: | August 24, 2011 |
| Health Authority: | United States: Federal Government |
Keywords provided by National Cancer Institute (NCI):
|
male breast cancer recurrent breast cancer recurrent colon cancer recurrent non-small cell lung cancer recurrent pancreatic cancer recurrent rectal cancer stage III colon cancer stage III pancreatic cancer stage III rectal cancer stage IIIA breast cancer |
stage IIIB breast cancer stage IIIC breast cancer stage IV breast cancer stage IV colon cancer stage IV non-small cell lung cancer stage IV rectal cancer stage IIIA non-small cell lung cancer stage IIIB non-small cell lung cancer stage IV pancreatic cancer |
Additional relevant MeSH terms:
|
Breast Neoplasms Colorectal Neoplasms Lung Neoplasms Pancreatic Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Intestinal Diseases |
Rectal Diseases Respiratory Tract Neoplasms Thoracic Neoplasms Lung Diseases Respiratory Tract Diseases Endocrine Gland Neoplasms Pancreatic Diseases Endocrine System Diseases Gemcitabine Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Antineoplastic Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 19, 2013